Given the ongoing changes within prostate cancer diagnostic and treatment pathways, Prostate Cancer UK commissioned a clinical consensus to ascertain expert opinion on optimal use of the PSA test in asymptomatic patients. This evidence concerns the gene KLK3 and prostate cancer.